Tekla Capital Management LLC Nektar Therapeutics Transaction History

Tekla Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $2.36 Million - $3.4 Million	-180,438 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$15.77 - $19.03 $1.3 Million - $1.57 Million	-82,641 Reduced 31.41%	180,438 $3.07 Million
Q1 2020 May 14, 2020	SELL	$14.47 - $27.96 $298,082 - $575,976	-20,600 Reduced 7.26%	263,079 $4.7 Million
Q1 2019 May 14, 2019	BUY	$31.58 - $46.35 $5.98 Million - $8.77 Million	189,295 Added 200.56%	283,679 $9.53 Million
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $3.59 Million - $6.69 Million	-118,085 Reduced 55.58%	94,384 $3.1 Million

Q3 2018 Nov 13, 2018	BUY	$46.46 - $68.49 $1.1 Million - $1.62 Million	23,700 Added 12.56%	212,469 $13 Million
Q2 2018 Aug 13, 2018	BUY	$46.25 - $104.45 $2.97 Million - $6.71 Million	64,252 Added 51.6%	188,769 $9.22 Million
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $7.15 Million - $13.5 Million	124,517 New	124,517 $13.2 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.